In the last trading session, 2.28 million Fate Therapeutics Inc (NASDAQ:FATE) shares changed hands as the company’s beta touched 2.00. With the company’s per share price at $1.66 changed hands at -$0.02 or -1.19% during last session, the market valuation stood at $191.34M. FATE’s last price was a discount, traded about -431.93% off its 52-week high of $8.83. The share price had its 52-week low at $1.59, which suggests the last value was 4.22% up since then. When we look at Fate Therapeutics Inc’s average trading volume, we note the 10-day average is 4.41 million shares, with the 3-month average coming to 2.71 million.
Analysts gave the Fate Therapeutics Inc (FATE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.53. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended FATE as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Fate Therapeutics Inc’s EPS for the current quarter is expected to be -0.43.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Instantly FATE was in red as seen at the end of in last trading. With action -17.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -55.61%, with the 5-day performance at -17.00% in the red. However, in the 30-day time frame, Fate Therapeutics Inc (NASDAQ:FATE) is -19.81% down. Looking at the short shares, we see there were 11.35 million shares sold at short interest cover period of 3.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 66.8% from its current market value. According to analyst projections, FATE’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -201.2% plunge from its current level, while the stock would need to soar -201.2% for it to hit the projected low.
Fate Therapeutics Inc (FATE) estimates and forecasts
Data shows that the Fate Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -55.38% over the past 6 months, a -4.88% in annual growth rate that is considerably lower than the industry average of 17.20%. Year-over-year growth is forecast to reach -78.52% down from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 1.57M. 10 analysts are of the opinion that Fate Therapeutics Inc’s revenue for the current quarter will be 1.2M. The company’s revenue for the corresponding quarters a year ago was 1.68M and 1.93M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.49%. The estimates for the next quarter sales put growth at -37.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -6.65%. The 2024 estimates are for Fate Therapeutics Inc earnings to increase by 0.38%.
FATE Dividends
Fate Therapeutics Inc is expected to release its next quarterly earnings report in January.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.17% of Fate Therapeutics Inc shares while 102.25% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 104.52%. There are 102.25% institutions holding the Fate Therapeutics Inc stock share, with REDMILE GROUP, LLC the top institutional holder. As of 2024-06-30, the company held 13.0252% of the shares, roughly 13.17 million FATE shares worth $43.19 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.4544% or 10.57 million shares worth $34.67 million as of 2024-06-30.
